MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12325-026-03641-0

Медицинская библиотека · Advances in therapy · 2026

Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.

Mansinho André, Gramaça João Carlos, Ramos Rodrigo, Baltazar Pedro Miguel, Palma Dos Reis José, Fernandes Ricardo, Malheiro Mariana, Rosinha Alina, Amorim Sofia, Borges Ricardo, Braga Isaac, Capela Andreia, Carneiro Diogo Nunes, Dinis Rui, Ferreira André, Figueiredo Arnaldo, Lopes Sílvia, Madeira Pedro Silvestre, Magalhães Helena, Mansinho Hélder, Meireles Sara, Pereira Carolina, Pinto Cidália, Rodrigues Chiara, Spencer Ana, Carvalho Carolina, Tomás Tiago, Rabaça Carlos

СтатьяОбзорПеревод в очереди

Аннотация

Metastatic hormone-sensitive prostate cancer (mHSPC) is a disease state characterized by the presence of distant metastases detectable on conventional imaging while the tumor remains responsive to androgen deprivation therapy (ADT). It represents an earlier, treatment-sensitive phase that precedes the development of metastatic castration-resistant prostate cancer (mCRPC), the terminal stage of the disease. The addition of therapies beyond traditional ADT to achieve more sustained tumor regression by combining different mechanisms of action and targeting different cancer fuelling pathways has spurred the concept of treatment intensification in prostate cancer. This approach may involve the addition of androgen receptor pathway inhibitors (ARPIs) to ADT-hereafter referred to as "treatment intensification"-or the addition of ARPIs plus chemotherapy to ADT-hereafter referred to as "treatment optimization." Randomized controlled trials have consistently shown improved patient outcomes with the evolution from ADT alone to ADT plus ARPI, and more recently to ADT plus ARPI plus docetaxel, and demonstrated that treatment intensification decisions in mHSPC have clinically meaningful implications. However, in the absence of comparative efficacy data between therapy options, the treatment choice for a given patient will depend on patient- and disease-related factors, with the goal of improving outcomes while minimizing the cumulative toxicity of therapies, particularly when using combination strategies. In this article, a panel of 28 experts-8 urologists and 20 oncologists-with recognized experience and expertise in the management of advanced prostate cancer discussed the role of treatment intensification in mHSPC and which patients are more likely to benefit from each treatment strategy.

Для цитирования: Mansinho André, Gramaça João Carlos, Ramos Rodrigo, Baltazar Pedro Miguel, Palma Dos Reis José, Fernandes Ricardo, Malheiro Mariana, Rosinha Alina, Amorim Sofia, Borges Ricardo, Braga Isaac, Capela Andreia, Carneiro Diogo Nunes, Dinis Rui, Ferreira André, Figueiredo Arnaldo, Lopes Sílvia, Madeira Pedro Silvestre, Magalhães Helena, Mansinho Hélder, Meireles Sara, Pereira Carolina, Pinto Cidália, Rodrigues Chiara, Spencer Ana, Carvalho Carolina, Tomás Tiago, Rabaça Carlos. Therapy Optimization in mHSPC: Insights from a Multidisciplinary Uro-Oncology Expert Panel.. Advances in therapy. 2026. DOI: 10.1007/s12325-026-03641-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.